Expense Ratio

In insurance, the expense ratio is a financial metric that represents the amount of an insurer's expenses compared to its premium income. The expense ratio is calculated by dividing an insurer's expenses (including underwriting, policy issuance, and administrative costs) by its premium income. The resulting percentage represents the insurer's efficiency in managing its expenses.

For example, if an insurer has $100 million in expenses and $500 million in premiums, its expense ratio would be 20%. This means that for every dollar of premium income received, the insurer spends 20 cents on expenses.

Key features of the expense ratio in insurance include:

·      It is a measure of an insurer's efficiency inmanaging its expenses.

·      A lower expense ratio indicates that an insureris more efficient at managing its expenses and may be able to offer lowerpremiums to policyholders.

·      The expense ratio can vary widely betweendifferent insurers and different lines of insurance.

·      Insurers may adjust their expense ratios overtime by changing their business practices or implementing cost-cuttingmeasures.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.